Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Decade in review—hypertension

The past decade in hypertension—facts, hopes, and hypes

Hypertension research in the past decade has been a mixture of hope and hype. In the absence of new drug developments, clinical intervention procedures such as renal nerve ablation and baroreflex activation therapy have dominated the research, but the results have not yet fulfilled the great expectations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The hits and misses in the development of blood-pressure lowering therapies during the past decade.

References

  1. Krum, H. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373, 1275–1281 (2009).

    Article  Google Scholar 

  2. Bhatt, D. L. et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370, 1393–1401 (2014).

    Article  CAS  Google Scholar 

  3. Tissot, A. C. et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371, 821–827 (2008).

    Article  CAS  Google Scholar 

  4. Bisognano, J. D. et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J. Am. Coll. Cardiol. 58, 765–773 (2011).

    Article  Google Scholar 

  5. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547–1559 (2008).

    Article  CAS  Google Scholar 

  6. Yusuf, S. et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372, 1174–1183 (2008).

    Article  CAS  Google Scholar 

  7. Yang, G. et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322, 587–590 (2008).

    Article  CAS  Google Scholar 

  8. Barhoumi, T. et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57, 469–476 (2011).

    Article  CAS  Google Scholar 

  9. Hess, K., Marx, N. & Lehrke, M. Cardiovascular disease and diabetes: the vulnerable patient. Eur. Heart J. Suppl. 14, B4–B13 (2012).

    Article  Google Scholar 

  10. Newton-Cheh, C. et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41, 666–676 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas Unger.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Unger, T. The past decade in hypertension—facts, hopes, and hypes. Nat Rev Cardiol 11, 633–635 (2014). https://doi.org/10.1038/nrcardio.2014.131

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.131

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing